Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study – ANNALS OF ONCOLOGY

Passaro, A; Wang, J; Wang, Y; Lee, SH; Melosky, B; Shih, JY; Wang, J; Azuma, K; Juan-Vidal, O; Cobo, M; Felip, E; Girard, N; Cortot, AB; Califano, R; Cappuzzo, F; Owen, S; Popat, S; Tan, JL; Salinas, J; Tomasini, P; Gentzler, RD; William, WN Jr; Reckamp, KL;...

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial – JOURNAL FOR IMMUNOTHERAPY OF CANCER

Carbone, DP; Ciuleanu, TE; Schenker, M; Cobo, M; Bordenave, S; Juan-Vidal, O; Menezes, J; Reinmuth, N; Richardet, E; Cheng, Y; Mizutani, H; Felip, E; Zurawski, B; Alexandru, A; Paz-Ares, L; Lu, S; John, T; Zhang, XQ; Mahmood, J; Hu, N; De, TL; Santi, I; Penrod, JR;...